Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.
In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.
Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.
Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.
Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.
Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.
Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.
What is Steven Robert Pacelli's net worth?
The estimated net worth of Steven Robert Pacelli is at least $9.39 million as of November 24th, 2023. Mr. Pacelli owns 124,775 shares of DexCom stock worth more than $9,388,071 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Pacelli may own. Learn More about Steven Robert Pacelli's net worth.
How do I contact Steven Robert Pacelli?
Has Steven Robert Pacelli been buying or selling shares of DexCom?
Steven Robert Pacelli has not been actively trading shares of DexCom during the past quarter. Most recently, Steven Robert Pacelli sold 411 shares of the business's stock in a transaction on Friday, November 24th. The shares were sold at an average price of $110.80, for a transaction totalling $45,538.80. Following the completion of the sale, the director now directly owns 124,775 shares of the company's stock, valued at $13,825,070. Learn More on Steven Robert Pacelli's trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 9/9/2024.